A cutaneous melanoma mouse model was used to test the efficacy of a new therapeutical approach that uses low doses of cytostatics in conjunction with mild whole body microwave exposure of 2.45？GHz in order to enhance cytostatics antitumoral effect. Materials and Methods. A microwave exposure system for C57BL/6 mouse whole body microwave irradiation was designed; groups of 40 mice (males and females) bearing experimental tumours were subjected to a combined therapy comprising low doses of dacarbazine in combination with mild whole body irradiation. Clinical parameters and serum cytokine testing using xMAP technology were performed. Results. The group that was subjected to combined therapy, microwave and cytostatic, had the best clinical evolution in terms of overall survival, tumour volume, and metastatic potential. At day 14 the untreated group had 100% mortality, while in the combined therapy group 40% of mice were surviving. Quantifying serum IL-1β, IL-6, IL-10, IL-12 (p70), IFN-γ, GM-CSF, TNF-α, MIP-1α, MCP-1, and KC during tumorigenesis and therapy found that the combined experimental therapy decreases all the inflammatory cytokines, except chemokine MCP-1 that was found increased, suggesting an increase of the anti-tumoral immune response triggered by the combined therapy. The overall metastatic process is decreased in the combined therapy group. 1. Introduction Malignant melanoma (MM) is one of the most aggressive human cancers, since a few mm thick tumors have full potential to kill the host in more than 80% of the cases [1]. Besides the surgical elimination of the primary tumor, there is no other effective cure for MM [1, 2]. MM is resistant to ionizing radiations (radiotherapies) as well as to conventional chemotherapies. The combination of ionizing radiation as well as nonionizing radiation (such as microwaves) with other therapies is reported as a promising strategy in cancer therapy [2]. Microwaves (MW) are presently used or under study for therapeutic applications in areas such as cardiology, urology, general surgery, ophthalmology, and oncology. MW is used as well for organ imaging in the clinical diagnostic of cancer [3]. In the last years there is a revival of therapeutical possibilities to use MW in oncology, in both animal in vivo models studies and in clinical trials. Low-intensity microwave radiation used in animal model inoculated with sarcoma 45 cell line has shown that in 50% of animals’ tumor growth and partial regression was obtained. The treatment was efficient due to the actual destruction of tumors and accumulation of
References
[1]
J. Tímár, L. Mészáros, A. Ladányi, L. G. Puskás, and E. Rásó, “Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies,” Cellular Immunology, vol. 244, no. 2, pp. 154–157, 2006.
[2]
J. Yang, G. Jin, X. Liu, and S. Liu, “Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice,” Human Gene Therapy, vol. 18, no. 4, pp. 323–332, 2007.
[3]
A. Rosen, M. A. Stuchly, and A. Vander Vorst, “Applications of RF/microwaves in medicine,” IEEE Transactions on Microwave Theory and Techniques, vol. 50, no. 3, pp. 963–974, 2002.
[4]
T. N. Gudzkova, G. V. Zhukova, L. H. Garkavi, M. I. Sukhanova, O. F. Evstratova, and T. A. Barteneva, “Morphofuctional aspects of antitumor activity of low-intensity microwave resonance radiation in experiment,” Bulletin of Experimental Biology and Medicine, vol. 150, no. 5, pp. 659–663, 2011.
[5]
W. Fan, X. Li, L. Zhang, H. Jiang, and J. Zhang, “Comparison of microwave ablation and multipolar radiofrequency ablation in vivo using two internally cooled probes,” American Journal of Roentgenology, vol. 198, no. 1, pp. W46–W50, 2012.
[6]
Y. Liu, S. Li, X. Wan et al., “Efficacy and safety of thermal ablation in patients with liver metastases,” European Journal of Gastroenterology & Hepatology, vol. 25, no. 4, pp. 442–446, 2013.
[7]
Y.-C. Hu, J.-T. Ji, and D.-X. Lun, “Intraoperative microwave inactivation in-situ of malignant tumors in the scapula,” Orthopaedic Surgery, vol. 3, no. 4, pp. 229–235, 2011.
[8]
K. Saito, K. Tsubouchi, M. Takahashi, and K. Ito, “Practical evaluations on heating characteristics of thin microwave antenna for intracavitary thermal therapy,” Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, pp. 2755–2758, 2010.
[9]
M. Palazzi, S. Maluta, S. Dall'Oglio, and M. Romano, “The role of hyperthermia in the battle against cancer,” Tumori, vol. 96, no. 6, pp. 902–910, 2010.
[10]
R. C. Ward, T. T. Healey, and D. E. Dupuy, “Microwave ablation devices for interventional oncology,” Expert Review of Medical Devices, vol. 10, no. 2, pp. 225–238, 2013.
[11]
S. M. Michaelson and E. C. Elson, “Interaction of nonmodulated and pulse modulated radiofrequency fields with living matter: experimental result,” in Handbook of Biological Effects of Electromagnetic Fields, CRC Press, 1996.
[12]
W. R. Adey, “Biological effects of radiofrequency electromagnetic radiation,” in Interaction of Electromagnetic Waves With Biological Systems, J. C. Lin, Ed., Plenum Press, New York, NY, USA, 1998.
[13]
U. Kaatze, “Fundamentals of microwaves,” Radiation Physics and Chemistry, vol. 45, no. 4, pp. 539–548, 1995.
[14]
M. A. Emekaya, N. Seyhan, and S. ？mero？lu, “Pulse modulated 900 MHz radiation induces hypothyroidism and apoptosis in thyroid cells: a light, electron microscopy and immunohistochemical study,” International Journal of Radiation Biology, vol. 86, no. 12, pp. 1106–1116, 2010.
[15]
“CSIRO Report, Biological Effects and Safety of EMR,” June 1994, http://electricwords.emfacts.com/csiro.
[16]
M.-C. Parker, T. Besson, S. Lamare, and M.-D. Legoy, “Microwave radiation can increase the rate of enzyme-catalysed reactions in organic media,” Tetrahedron Letters, vol. 37, no. 46, pp. 8383–8386, 1996.
[17]
H. Bohr and J. Bohr, “Microwave-enhanced folding and denaturation of globular proteins,” Physical Review E, vol. 61, no. 4B, pp. 4310–4314, 2000.
[18]
I. Trosic, I. Busljeta, V. Kasuba, and R. Rozgaj, “Micronucleus induction after whole-body microwave irradiation of rats,” Mutation Research, vol. 521, no. 1-2, pp. 73–79, 2002.
[19]
I. Trosic, I. Busljeta, and B. Modlic, “Investigation of the genotoxic effect of microwave irradiation in rat bone marrow cells: in vivo exposure,” Mutagenesis, vol. 19, no. 5, pp. 361–364, 2004.
[20]
K. K. Kesari and J. Behari, “Effects of microwave at 2.45 GHz radiations on reproductive system of male rats,” Toxicological & Environmental Chemistry, vol. 92, no. 6, pp. 1135–1147, 2010.
[21]
M. K. Logani, I. Szabo, V. Makar, A. Bhanushali, S. Alekseev, and M. C. Ziskin, “Effect of millimeter wave irradiation on tumor metastasis,” Bioelectromagnetics, vol. 27, no. 4, pp. 258–264, 2006.
[22]
I. Green, Hyperthermia in Conjunction with Cancer Chemeotherapy, Health Technology Assessment 2 Rockville, U.S. Department of Health and Human Services, 1991, http://www.ahcpr.gov/clinic/hypther2.htm.
[23]
D. M. Katschinski, G. J. Wiedemann, W. Longo, F. R. d'Oleire, D. Spriggs, and H. I. Robins, “Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy,” Cytokine & Growth Factor Reviews, vol. 10, no. 2, pp. 93–97, 1999.
[24]
B. Hildebrandt, P. Wust, O. Ahlers et al., “The cellular and molecular basis of hyperthermia,” Critical Reviews in Oncology/Hematology, vol. 43, no. 1, pp. 33–56, 2002.
[25]
D. Jia, W. Rao, C. Wang et al., “Inhibition of B16 murine melanoma metastasis and enhancement of immunity by fever-range whole body hyperthermia,” International Journal of Hyperthermia, vol. 27, no. 3, pp. 275–285, 2011.
[26]
L. M. Mir, “Therapeutic perspectives of in vivo cell electropermeabilization,” Bioelectrochemistry, vol. 53, no. 1, pp. 1–10, 2001.
[27]
T. Kotnik, A. Ma？ek-Lebar, D. Miklav？i？, and L. M. Mir, “Evaluation of cell membrane electropermeabilization by means of a nonpermeant cytotoxic agent,” BioTechniques, vol. 28, no. 5, pp. 921–926, 2000.
[28]
S. Satkauskas, M. F. Bureau, M. Puc et al., “Mechanisms of in vivo DNA electrotransfer: respective contribution of cell electropermeabilization and DNA electrophoresis,” Molecular Therapy, vol. 5, no. 2, pp. 133–140, 2002.
[29]
A. Gothelf, L. M. Mir, and J. Gehl, “Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation,” Cancer Treatment Reviews, vol. 29, no. 5, pp. 371–387, 2003.
[30]
V. Mu？oz Madero and G. Ortega Pérez, “Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy,” Clinical and Translational Oncology, vol. 13, no. 1, pp. 18–24, 2011.
[31]
D. Martin, S. Cinca, I. Margaritescu et al., “Combined microwave and electron beam exposure facilities for medical studies and applications,” Journal of Microwave Power & Electromagnetic Energy, vol. 43, no. 3, pp. 12–20, 2009.
[32]
T. DiChiara, “Cancer Chemotherapy for Melanoma: Dacarbazine a Patient's Guide to Cancer Chemotherapy with Dacarbazine,” 2009, http://skincancer.about.com/od/treatmentoptions/a/melanoma_chemo.htm.
[33]
A. Y. Bedikian, M. Millward, H. Pehamberger et al., “Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4738–4745, 2006.
[34]
D. C. Lev, A. Onn, V. O. Melinkova et al., “Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2092–2100, 2004.
[35]
X. H. Zhang, E. Q. Qiao, Z. Gao et al., “Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model,” Oncology Letters, vol. 6, no. 1, pp. 69–74, 2013.
[36]
Z. Wang, J. Chen, J. Wang et al., “Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis,” Pharmaceutical Research, vol. 29, no. 11, pp. 3040–3052, 2012.
[37]
W. W. Overwijk and N. P. Restifo, “B16 as a mouse model for human melanoma,” Current Protocols in Immunology, vol. 39, pp. 20.1.1–20.1.29, 2001.
[38]
Guide for the Care and Use of Laboratory Animals, Committee for the Update of the Guide for the Care and Use of Laboratory Animals, National Research Council, 8th edition, 2010.
[39]
D. Martin, A. Jianu, and D. Ighigeanu, “A method for the 2.45-GHz magnetron output power control,” IEEE Transactions on Microwave Theory and Techniques, vol. 49, no. 3, pp. 542–545, 2001.
[40]
C. Persch and H. Schubert, “Characterization of household microwave ovens by their efficiency and quality parameter,” in Proceedings of the 5th International Conference on Microwave and High Frequency Heating, pp. S31.1–S31.4, Cambridge, UK, 1995.
[41]
I. K. Egorov, “Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape,” Cancer Immunology, Immunotherapy, vol. 55, no. 1, pp. 1–22, 2006.
[42]
H. Winter, N. K. van den Engel, D. Rüttinger et al., “Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines,” Journal of Translational Medicine, vol. 5, article no. 56, 2007.
[43]
K. Wetzel, S. Struyf, J. Van Damme et al., “MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells,” International Journal of Cancer, vol. 120, no. 6, pp. 1364–1371, 2007.
[44]
M. K. Logani, A. Bhanushali, A. Anga, A. Majmundar, I. Szabo, and M. C. Ziskin, “Combined millimeter wave and cyclophosphamide therapy of an experimental murine melanoma,” Bioelectromagnetics, vol. 25, no. 7, pp. 516–523, 2004.
[45]
M. Koga, H. Kai, K. Egami et al., “Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice,” Biochemical and Biophysical Research Communications, vol. 365, no. 2, pp. 279–284, 2008.
[46]
C. E. Redona, J. S. Dickeya, A. J. Nakamuraa et al., “Tumors induce complex DNA damage in distant proliferative tissues in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 42, pp. 17992–17997, 2013.
[47]
M. Neagu, C. Constantin, and S. Zurac, “Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations,” BioMed Research International, vol. 2013, Article ID 107940, 13 pages, 2013.
[48]
G. Pietro and C. Roca, “Results of hyperthermia alone or with radiation therapy and/or chemotherapy,” in Hyperthermia in Cancer Treatment: A Primer, Medical Intelligence Unit, pp. 119–127, 2006.
[49]
P. K. Jain, I. H. ElSayed, and M. A. El-Sayed, “Au nanoparticles target cancer,” Nano Today, vol. 2, no. 1, pp. 18–29, 2007.
[50]
M. Fukugawa, M. Kitaoka, Y. Tominaga et al., “Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients,” Nephrology Dialysis Transplantation, vol. 18, no. 3, pp. iii31–iii33, 2003.
[51]
J. E. de Barros Gueiros, M. C. Chammas, R. Gerhard et al., “Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism,” Nephrology Dialysis Transplantation, vol. 19, no. 3, pp. 657–663, 2004.
[52]
R. D. Kovatcheva, J. D. Vlahov, J. I. Stoinov et al., “High-intensity focussed ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 76–80, 2012.
[53]
F. Alongi, R. L. Liardo, C. Iftode et al., “11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicity,” Technology in Cancer Research and Treatment, 2013.
